Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy.
Activities of Daily Living
Aged
Anxiety
/ psychology
Depression
/ psychology
Fatigue
/ physiopathology
Female
Hand Strength
Humans
Male
Middle Aged
Multivariate Analysis
Muscle Strength
/ physiology
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
/ physiopathology
Quality of Life
Sensory Thresholds
/ physiology
CIDP
depression
experienced
fatigue
peripheral neuropathy
quality of life
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
23
12
2019
revised:
01
05
2020
accepted:
03
05
2020
pubmed:
11
5
2020
medline:
26
9
2020
entrez:
11
5
2020
Statut:
ppublish
Résumé
Fatigue is a recognized manifestation of immune-mediated neuropathies, but its causes and implications are unclear. In this study, we explored the correlates of fatigue among a number of clinical parameters in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) to better understand potential contributing factors and resulting consequences. Twenty-six clinically stable patients with CIDP underwent assessments of motor and sensory function, disability, quality of life, and depression and anxiety. Experienced fatigue was assessed by using the Rasch-built Fatigue Severity Scale and the Checklist of Individual Strength. The two fatigue scales provided evidence of significant intercorrelation. Only depression scores and grip strength predicted experienced fatigue levels in multivariate regression analyses. Fatigue scores inversely correlated with strength, sensory, disability, and quality of life scores. Experienced fatigue is likely multifactorial in CIDP, with both physical and neuropsychiatric components. Fatigue is associated with lower functional and quality-of-life outcomes in CIDP.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-232Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363:978-988.
Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 1999;53:1648-1654.
Merkies I, Faber C. Fatigue in immune-mediated neuropathies. Neuromuscul Disord. 2012;Suppl 3:S203-S207.
Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev. 2001;81:1725-1789.
Zwarts MJ, Bleijenberg G, van Engelen BGM. Clinical neurophysiology of fatigue. Clin Neurophysiol. 2008;119:2-10.
Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res. 2004;56:157-170.
Garssen MPJ, Schillings ML, Van Doorn PA, Van Engelen BGM, Zwarts MJ. Contribution of central and peripheral factors to residual fatigue in Guillain-Barre syndrome. Muscle Nerve. 2007;36:93-99.
Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14:310-315.
Westblad ME, Forsberg A, Press R. Disability and health status in patients with chronic inflammatory demyelinating polyneuropathy. Disabil Rehabil. 2009;31:720-725.
Boukhris S, Magy L, Gallouedec G, et al. Fatigue as the main presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy: a study of 11 cases. J Peripher Nerv Syst. 2005;10:329-337.
Drenthen J, Jacobs BC, Maathuis EM, van Doorn PA, Visser GH, Blok JH. Residual fatigue in Guillain-Barre syndrome is related to axonal loss. Neurology. 2013;81:1827-1831.
Forsberg A, Press R, Holmqvist LW. Residual disability 10 years after falling ill in Guillain-Barre syndrome: a prospective follow-up study. J Neurol Sci. 2012;317:74-79.
Drory VE, Bronipolsky T, Bluvshtein V, Catz A, Korczyn AD. Occurrence of fatigue over 20 years after recovery from Guillain-Barre syndrome. J Neurol Sci. 2012;316:72-75.
Davidson I, Wilson C, Walton T, Brissenden S. Physiotherapy and Guillain-Barre syndrome: results of a national survey. Physiotherapy. 2009;95:157-163.
Garssen MPJ, Van Koningsveld R, Van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome. J Neurol. 2006;253:1143-1146.
Merkies ISJ, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75:199-206.
Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:356-363.
Lawley A, Seri S, Rajabally YA. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: a potential role in monitoring response to intravenous immunoglobulins. Clin Neurophysiol. 2019;130:1743-1749.
Collen F, Wade D, Bradshaw C. Mobility after stroke: reliability of measures of impairment and disability. Int Disabil Stud. 1990;12:6-9.
van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76:337-345.
Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77:973-976.
Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160-164.
van Nes SI, Vanhoutte EK, Faber CG, Garssen M, van Doorn PA, Merkies ISJ. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst. 2009;14:268-278.
Vercoulen J, Swanink C, Fennis J, Galama J, van der Meer J, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383-392.
Kalkman JS, Schillings ML, Van Der Werf SP, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005;76:1406-1409.
Jagersma E, Jeukens-Visser M, van Paassen BW, Meester-Delver A, Nollet F. Severe fatigue and reduced quality of life in children with hereditary motor and sensory neuropathy 1A. J Child Neurol. 2013;28:429-434.
Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
Garssen MPJ, Bussmann JBJ, Schmitz PIM, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology. 2004;63:2393-2395.
Gregory R. Understanding and coping with neurological impairment. Rehabil Nurs. 1995;20:74-78.
Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BGM, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571-579.
Boentert M, Dziewas R, Heidbreder A, et al. Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey. J Neurol. 2010;257:646-652.
Menotti F, Berchicci M, Di Russo F, Damiani A, Vitelli S, Macaluso A. The role of the prefrontal cortex in the development of muscle fatigue in Charcot-Marie-Tooth 1A patients. Neuromuscul Disord. 2014;24:516-523.
Garssen MPJ, Schmitz PIM, Merkies ISJ, Jacobs BC, van der Meche FGA, van Doorn PA. Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry. 2006;77:61-65.
Bayas A, Schuh K, Baier M, Vormfelde SV. Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN. Ther Adv Neurol Disord. 2016;9:378-388.
Rajabally YA, Seri S, Cavanna AE. Neuropsychiatric manifestations in inflammatory neuropathies: a systematic review. Muscle Nerve. 2016;54:1-8.